CD117 and Desmin Positive, S100 Negative Lesion
This immunohistochemical profile is most consistent with a gastrointestinal stromal tumor (GIST), and you should immediately order DOG1 staining and pursue KIT/PDGFRA mutational analysis to confirm the diagnosis and guide treatment.
Diagnostic Approach
The immunoprofile you describe—CD117 positive, desmin positive, S100 negative—strongly suggests GIST, though the desmin positivity is atypical and requires careful consideration.
Key Diagnostic Features
Standard GIST immunoprofile:
- Over 95% of GISTs express CD117 (c-KIT) with diffuse cytoplasmic staining 1
- 70-90% express CD34 1
- Only 2-4% of typical GISTs express desmin 1
- 8-10% express S-100 1
Your case shows desmin positivity, which is unusual but not impossible for GIST. Notably, Kit-negative GISTs paradoxically show desmin expression in approximately 30% of cases, especially in gastric lesions with epithelioid morphology 1. While your lesion is CD117-positive, this suggests that desmin expression can occur in the GIST spectrum, particularly in certain subtypes.
Critical Next Steps
Immediately order these additional tests:
DOG1 (ANO1) immunostaining - This is nearly pathognomonic for GIST and should be included in the initial panel 1. DOG1 confirms GIST diagnosis when CD117 and/or DOG1 are positive.
CD34 immunostaining - Expected to be positive in 70-90% of GISTs 1
KIT and PDGFRA mutational analysis - This is mandatory and should be considered standard practice 2. This has both diagnostic confirmation value and critical predictive value for targeted therapy sensitivity.
Mitotic count - Must be expressed as number of mitoses per 5 mm² total area (not per high-power field) 1
Differential Diagnosis Considerations
The S100 negativity effectively rules out schwannoma (which would be strongly S100-positive) 1.
However, the desmin positivity raises concern for:
- Smooth muscle tumors (leiomyoma/leiomyosarcoma) - but these are typically CD117-negative and both SMA and desmin positive 3
- Atypical GIST variant - particularly if gastric location with epithelioid features
- Other rare entities - though less likely given CD117 positivity
Critical pitfall: True smooth muscle tumors (leiomyomas from esophagus, muscularis mucosae, pericolic locations) are negative for both CD117 and CD34 but positive for SMA and desmin 4. Your CD117 positivity argues strongly against this.
Treatment Algorithm
If GIST is Confirmed:
1. Risk Stratification (mandatory reporting elements) 1:
- Tumor location (stomach vs. small bowel vs. other)
- Tumor size (three-dimensional measurement)
- Mitotic count per 5 mm²
- Margin status
- Presence of tumor rupture or necrosis
2. Localized/Resectable Disease:
- Complete surgical resection with negative margins is the primary treatment
- No tumor rupture during surgery (associated with poor prognosis)
- Consider adjuvant imatinib for moderate-to-high risk tumors based on risk stratification
3. Advanced/Metastatic Disease Treatment Sequence:
First-line: Imatinib 400 mg daily 5, 6
- Exception: If KIT exon 9 mutation detected, start with 800 mg daily (these are hyposensitive to standard dosing) 3
- Monitor plasma levels if: drug interactions present, unexpected toxicity, or progression on 400 mg 5
Upon progression on 400 mg imatinib:
- Increase to 800 mg daily 5, 6 (unless insensitive mutation like PDGFRA D842V)
- Rule out non-compliance and drug interactions first
- Standard: 50 mg for 4 weeks on/2 weeks off
- Alternative: 37.5 mg continuous daily dosing (better tolerated, though not formally compared) 5
Third-line: Regorafenib 160 mg daily (3 weeks on/1 week off) 5
Special Molecular Considerations
If KIT/PDGFRA wild-type GIST:
- Perform SDHB immunohistochemistry 1
- If SDHB-deficient, consider germline SDH mutation testing (familial syndrome implications) 2, 7
- Consider testing for BRAF mutations and NTRK fusions (rare but therapeutically relevant) 2, 7
Critical Management Points
Refer to specialized sarcoma center if:
- Atypical morphology or immunoprofile (like your case with desmin positivity)
- CD117 and DOG1 both negative
- Wild-type for KIT/PDGFRA 1
Surgical considerations for metastatic disease:
- Complete excision of residual metastatic disease may be beneficial only if responding to imatinib 5
- Surgery for limited progression ("nodule within a mass") while continuing imatinib is an option 5, 6
- Avoid surgery for diffuse progression - not beneficial in retrospective series 5
Common pitfall: GIST dedifferentiation can occur either de novo or after chronic imatinib exposure, potentially losing CD117 expression 1. This represents genetic instability rather than additional KIT mutations.
The desmin positivity in your case is unusual but documented in the GIST literature, particularly in certain subtypes. Proceed with DOG1 staining and mutational analysis immediately - these will be definitive for diagnosis and essential for treatment planning 1, 2, 7.